What's Happening?
Novo Nordisk has presented new data indicating that a stronger dose of its weight-loss drug Wegovy has led to significant weight loss in patients. The findings were shared at the European Congress on Obesity in Istanbul, focusing on a 7.2 mg dose of semaglutide,
the active ingredient in Wegovy. This dose was compared to the standard 2.4 mg dose and a placebo in the STEP UP clinical trial, which followed adults with obesity over 72 weeks. Patients on the higher dose lost an average of 21% of their body weight, with some early responders losing up to 27.7%. The study also highlighted that 84% of the weight loss was from fat, preserving muscle function. The higher dose has been approved in the U.S. and Europe, and is under registration in Israel.
Why It's Important?
The introduction of a more effective dose of Wegovy could significantly impact the weight-loss drug market, intensifying competition with Eli Lilly's Mounjaro. The new data suggests that the higher dose of Wegovy could offer comparable weight-loss results to Mounjaro, which previously had a market advantage. This development is crucial for patients seeking effective obesity treatments, as it provides an alternative that may offer better outcomes for certain individuals. Additionally, the findings could influence healthcare policies and funding decisions, particularly in regions like Israel, where obesity treatments are gaining recognition as essential healthcare services.
What's Next?
The new data is likely to fuel discussions about the accessibility and funding of Wegovy in healthcare systems worldwide. As the drug gains approval in more regions, healthcare providers may need to consider its integration into treatment plans for obesity. Further studies and peer-reviewed publications will be necessary to validate the findings and address any long-term implications of using the higher dose. The competition between Novo Nordisk and Eli Lilly is expected to continue, potentially leading to further innovations and improvements in weight-loss treatments.
